Synapse - Global Drug Intelligence Database

JMC Annotation Spotlight: Analysis of Breakthrough Therapeutics

This report features four highly representative and innovative therapeutics recently profiled in the JMC Annotation column (submitted before December 2024 and with no clinical failure reported to date). The selection spans a diverse range of modalities, including covalent inhibitors, receptor-selective agonists, and CNS-penetrant compounds. The drugs are being developed by leading pharmaceutical and biotech companies such as Chiesi Farmaceutici S.p.A., Galapagos, Scorpion Therapeutics, and AstraZeneca.Through a systematic examination of the R&D paths of these compounds, this report aims to uncover their therapeutic potential, while also offering insight into their commercial prospects and developmental challenges.

Read →

Global Drug R&D Express (February 2025)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of February, totaling 120 drugs. Among them, 1 first-to-market drugs and 1 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →

Global Potential Targets and FIC Product Research Report (Q4 2024)

1，A comprehensive review was conducted of the 55 new drugs approved by the FDA in 2023, including 20 First-in-Class (FIC) therapies. Additionally, an analysis was performed on 8 promising FIC single-target agents and 10 FIC dual-target agents with significant potential for the first three quarters of 2024. 2，This report provides a comprehensive overview of the promising First-in-Class (FIC) single-target and dual-target agents anticipated for the fourth quarter of 2024. It includes detailed analyses of their mechanisms of action, current research and development progress, and potential clinical applications. 3，Depth Analysis of Potential Single-target FIC Varieties: This section provides an in-depth examination of the following single-target First-in-Class (FIC) agents: LTCC modulators, M2R allosteric modulators, S2R modulators, BRD4 BD2 inhibitors, PKMYT1 inhibitors, TAK1 inhibitors, NLRP3 inhibitors, and oral KRAS G12D inhibitors. The analysis covers their mechanisms of action, current research progress, and patent application status. 4, In-depth Analysis of Potential Dual-Target FIC Varieties: This section provides a comprehensive examination of the FXR-LIFR dual-target regulators and ROCK-HDAC dual-target inhibitors, both of which are First-in-Class (FIC) compounds. The analysis delves into their development potential and patent landscape.

Read →